Zobrazeno 1 - 10
of 61
pro vyhledávání: '"Ian M. Waxman"'
Autor:
James Larkin, Jeffrey S. Weber, Hewei Li, Jedd D. Wolchok, Ian M. Waxman, Caroline Robert, Dirk Schadendorf, Joel Jiang, Suzanne L. Topalian, Georgina V. Long, F. Stephen Hodi, Mario Sznol
Publikováno v:
Journal of Clinical Oncology. 35:785-792
Purpose We conducted a retrospective analysis to assess the safety profile of nivolumab monotherapy in patients with advanced melanoma and describe the management of adverse events (AEs) using established safety guidelines. Patients and Methods Safet
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::98190b2e9855c2c7397981b386b410b3
https://doi.org/10.1200/jco.2015.66.1389
https://doi.org/10.1200/jco.2015.66.1389
Autor:
Jong-Soon Park, Paul Statkevich, Sally Saeger, Manish Gupta, Dharmesh D. Desai, Yan Feng, Shruti Agrawal, Ian M. Waxman, Gaurav Bajaj, Amit Roy
Publikováno v:
The Journal of Clinical Pharmacology. 57:394-400
Nivolumab is a fully human IgG4 monoclonal antibody targeting the programmed death-1 (PD-1) receptor that blocks interactions between PD-1 and its ligands on tumor cells to prevent T-cell exhaustion in patients with cancer. It has demonstrated effica
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::866aafbf303b0954a0e203487bba2f9a
https://doi.org/10.1002/jcph.818
https://doi.org/10.1002/jcph.818
Autor:
Paolo A. Ascierto, Amy P. Abernethy, Georgina V. Long, Fiona Taylor, Homa Dastani, Victoria Atkinson, Isabelle Gilloteau, Piotr Rutkowski, Caroline Robert, Kerry J. Savage, Ian M. Waxman, C. Coon, Jessica C. Hassel
Publikováno v:
Annals of Oncology
In patients with advanced melanoma in the CheckMate 066 study, baseline health-related quality of life (HRQoL) with nivolumab was maintained over time, with statistically significant and clinically meaningful improvements in some exploratory analyses
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2c7407a5a8ba2595d743659fa62f544f
http://europepmc.org/articles/PMC5035785
http://europepmc.org/articles/PMC5035785
Publikováno v:
Cancer Chemotherapy and Pharmacology. 77:635-641
The fully human monoclonal antibody nivolumab binds to the programmed death-1 (PD-1) receptor, blocking interactions between PD-1 and its ligands on tumor cells and preventing T cell exhaustion in patients with cancer. The potential for corrected QT
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f8fe4c05e7c33b7a191728f225007bcd
https://doi.org/10.1007/s00280-016-2980-3
https://doi.org/10.1007/s00280-016-2980-3
Autor:
David F. McDermott, Hans J. Hammers, Daniel Castellano, Padmanee Sharma, Katriina Peltola, Jeffrey A. Sosman, Bernard Escudier, Huanyu Zhao, Takeshi Ueda, Howard Gurney, Ian M. Waxman, Saby George, Elizabeth R. Plimack, John Wagstaff, Scott S. Tykodi, Frede Donskov, Thomas Gauler, Robert J. Motzer, Giuseppe Procopio, Sandhya Srinivas
Publikováno v:
CheckMate 025 Investigators 2018, ' Erratum to "CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma" [Eur Urol 2017;72:962-71] ', European Urology, vol. 73, no. 4, pp. e116-e118 . https://doi.org/10.1016/j.eururo.2017.12.016
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2da3f390fd8b9a209c43d7305df343fe
https://pure.au.dk/portal/da/publications/erratum-to-checkmate-025-randomized-phase-3-study-outcomes-by-key-baseline-factors-and-prior-therapy-for-nivolumab-versus-everolimus-in-advanced-renal-cell-carcinoma-eur-urol-20177296271(a75ba857-1960-4b17-b21a-2481334b3b55).html
https://pure.au.dk/portal/da/publications/erratum-to-checkmate-025-randomized-phase-3-study-outcomes-by-key-baseline-factors-and-prior-therapy-for-nivolumab-versus-everolimus-in-advanced-renal-cell-carcinoma-eur-urol-20177296271(a75ba857-1960-4b17-b21a-2481334b3b55).html
Autor:
Akintunde Bello, Xiaoning Wang, J. Shen, A. Achanta, H.E. Vezina, Yan Feng, Xiaochen Zhao, M. Hruska, Shruti Agrawal, Satyendra Suryawanshi, M.B. McHenry, Amit Roy, Ian M. Waxman
Publikováno v:
Annals of Oncology
Background Nivolumab 3 mg/kg every 2 weeks (Q2W) has shown benefit versus the standard of care in melanoma, non-small cell lung cancer (NSCLC), and renal cell carcinoma (RCC). However, flat dosing is expected to shorten preparation time and improve e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b7016d0217d6ef13192fa66f94c1e2cf
https://pubmed.ncbi.nlm.nih.gov/28520840
https://pubmed.ncbi.nlm.nih.gov/28520840
Autor:
Mary, Gerrard, Ian M, Waxman, Richard, Sposto, Anne, Auperin, Sherrie L, Perkins, Stanton, Goldman, Lauren, Harrison, Ross, Pinkerton, Keith, McCarthy, Martine, Raphael, Catherine, Patte, Mitchell S, Cairo
Publikováno v:
Blood. 121:278-285
Mediastinal large B-cell lymphoma (MLBL) represents 2% of mature B-cell non-Hodgkin lymphoma in patients ≤ 18 years of age. We analyzed data from childhood and adolescent patients with stage III MLBL (n = 42) and non-MLBL DLBCL (n = 69) treated wit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8abc80c2ca835131bbf186a6320f7275
https://doi.org/10.1182/blood-2012-04-422709
https://doi.org/10.1182/blood-2012-04-422709
Autor:
Shruti, Agrawal, Paul, Statkevich, Gaurav, Bajaj, Yan, Feng, Sally, Saeger, Dharmesh D, Desai, Jong-Soon, Park, Ian M, Waxman, Amit, Roy, Manish, Gupta
Publikováno v:
Journal of clinical pharmacology. 57(3)
Nivolumab is a fully human IgG4 monoclonal antibody targeting the programmed death-1 (PD-1) receptor that blocks interactions between PD-1 and its ligands on tumor cells to prevent T-cell exhaustion in patients with cancer. It has demonstrated effica
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::503aac5c0e94f20725c1c25da6ddd427
https://pubmed.ncbi.nlm.nih.gov/27557786
https://pubmed.ncbi.nlm.nih.gov/27557786
Autor:
Hans J. Hammers, Daniel Castellano, Thomas Gauler, Bernard Escudier, Huanyu Zhao, Howard Gurney, Jeffrey A. Sosman, Robert J. Motzer, Ian M. Waxman, Giuseppe Procopio, Frede Donskov, Sandhya Srinivas, David F. McDermott, Takeshi Ueda, John Wagstaff, Padmanee Sharma, Elizabeth R. Plimack, Saby George, Scott S. Tykodi, Petri Bono
Publikováno v:
Memorial Sloan Kettering Cancer Center
498 Background: Based on assessment by an independent Data Monitoring Committee, a phase III trial of NIVO (n=410) vs EVE (n=411) in previously treated patients with advanced or metastatic RCC (NCT01668784) was halted early as it met its endpoint; su
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e04e4fe3cab12112531b68acc434cb6a
Autor:
Vanna Chiarion-Sileni, Michele Maio, Victoria Atkinson, Ewa Kalinka-Warzocha, Caroline Robert, Christine Horak, Catalin Mihalcioiu, Laurent Mortier, Henrik Schmidt, Benjamin Brady, Dirk Schadendorf, Georgina V. Long, Julie Charles, Céleste Lebbé, Brian Sharkey, Paolo A. Ascierto, Ian M. Waxman, Micaela Hernberg, Caroline Dutriaux, Cornelia Mauch, Piotr Rutkowski, Catriona M. McNeil, Helen Gogas, Jessica C. Hassel, Kerry J. Savage
Publikováno v:
Journal of Translational Medicine
The hazard ratio (HR) for death was 0.42 (99.79% CI 0.25–0.73; P < 0.0001) in favor of nivolumab, with 1year OS rate 73% (95% CI, 66%–79%) for nivolumab vs 42% (95% CI, 33%–51%) for dacarbazine. Median OS was not reached for nivolumab and was 1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8be7ac479acdaec2aefbcf2c605055dd
https://doi.org/10.1186/1479-5876-13-s1-o6
https://doi.org/10.1186/1479-5876-13-s1-o6